Kilitch Drugs (India) (NSE:KILITCH) E10: ₹4.07 (As of Mar. 2026)


NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹185.31
GF Value ₹232.78
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) E10?

Kilitch Drugs (India) NSE:KILITCH -2.89% 84 E10 is ₹4.07 as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹232.78 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kilitch Drugs (India)'s adjusted earnings per share data for the three months ended in Mar. 2026 was ₹4.240. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹4.07 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kilitch Drugs (India)'s average E10 Growth Rate was 17.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Kilitch Drugs (India)'s current stock price is ₹185.31. Kilitch Drugs (India)'s E10 for the quarter that ended in Mar. 2026 was ₹4.07. Kilitch Drugs (India)'s Shiller PE Ratio of today is 45.53.

During the past 13 years, the highest Shiller PE Ratio of Kilitch Drugs (India) was 81.06. The lowest was 30.78. And the median was 53.30.


Kilitch Drugs (India)  (NSE:KILITCH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kilitch Drugs (India)'s Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=185.31/4.07
=45.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Kilitch Drugs (India) was 81.06. The lowest was 30.78. And the median was 53.30.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kilitch Drugs (India) E10 Related Terms


Kilitch Drugs (India) E10 Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) E10 Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.55 4.07

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.55 3.55 3.85 3.88 4.07

NSE:KILITCH vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kilitch Drugs (India) Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kilitch Drugs (India)'s Shiller PE Ratio falls into.


NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kilitch Drugs (India)'s adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.24/164.2724*164.2724
=4.240

Current CPI (Mar. 2026) = 164.2724.

Kilitch Drugs (India) Quarterly Data

per share eps CPI Adj_EPS
201209 -0.088 82.244 -0.176
201212 0.235 83.774 0.461
201303 0.176 85.687 0.337
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 1.258 111.317 1.856
201809 1.473 115.142 2.102
201812 -1.629 115.142 -2.324
201903 0.147 118.202 0.204
201906 -0.064 120.880 -0.087
201909 0.426 123.175 0.568
201912 0.303 126.235 0.394
202003 -0.396 124.705 -0.522
202006 -0.421 127.000 -0.545
202009 0.656 130.118 0.828
202012 0.700 130.889 0.879
202103 0.225 131.771 0.280
202106 0.372 134.084 0.456
202109 0.680 135.847 0.822
202112 0.352 138.161 0.419
202203 0.910 138.822 1.077
202206 0.656 142.347 0.757
202209 0.763 144.661 0.866
202212 0.744 145.763 0.838
202303 1.121 146.865 1.254
202306 1.052 150.280 1.150
202309 1.434 151.492 1.555
202312 0.905 152.924 0.972
202403 1.096 153.035 1.176
202406 0.406 155.789 0.428
202409 2.680 157.882 2.788
202412 1.855 158.323 1.925
202503 6.470 157.552 6.746
202506 0.920 159.755 0.946
202509 2.485 162.289 2.515
202512 1.250 163.281 1.258
202603 4.240 164.272 4.240

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹4.07 mean?
Kilitch Drugs (India) (NSE:KILITCH) has a E10 of ₹4.07 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s E10 too high?
Kilitch Drugs (India)'s current E10 is ₹4.07. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s E10 compare to ZTS and UTHR?
Kilitch Drugs (India)'s E10 of ₹4.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current E10 is ₹4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹232.78, compared to a current price of ₹185.31 — trading 20.4% below its estimated fair value. The current E10 is ₹4.07. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current E10 is ₹4.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹185.31 is trading 20.4% below its estimated GF Value™ of ₹232.78. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • E10: ₹4.07
  • GF Value™: ₹232.78 vs. price of ₹185.31 (20.4% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹185.31
Price
₹232.78
GF Value